These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17313464)

  • 1. Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients.
    Narreddy S; Mellon-Reppen S; Abidi MH; Klein JL; Peres E; Heilbrun LK; Smith D; Alangaden G; Chandrasekar PH
    Transpl Infect Dis; 2007 Mar; 9(1):3-10. PubMed ID: 17313464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation.
    Kornguth DG; Mahajan A; Woo S; Chan KW; Antolak J; Ha CS
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1140-4. PubMed ID: 17379444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
    Yamasaki S; Heike Y; Mori S; Fukuda T; Maruyama D; Kato R; Usui E; Koido K; Kim S; Tanosaki R; Tobinai K; Teshima T; Takaue Y
    Transpl Infect Dis; 2008 Jul; 10(4):252-9. PubMed ID: 18194371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.
    Huugen D; Bos GM; Jansen M; Lalisang R; Jansen R; Wagstaff J; Schouten HC
    Neth J Med; 2002 May; 60(4):170-3. PubMed ID: 12164395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation.
    Yoshimi A; Nannya Y; Sakata-Yanagimoto M; Oshima K; Takahashi T; Kanda Y; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Aug; 83(8):635-9. PubMed ID: 18506704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Luo L; Zhang L; Cai B; Li H; Huang W; Jing Y; Zhu H; Zhao Y; Bo J; Wang Q; Han X; Yu L; Gao C
    Ann Transplant; 2014 Jan; 19():6-12. PubMed ID: 24399278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation.
    Mossad SB; Avery RK; Longworth DL; Kuczkowski EM; McBee M; Pohlman BL; Sobecks RM; Kalaycio ME; Andresen SW; Macklis RM; Bolwell BJ
    Bone Marrow Transplant; 2001 Sep; 28(5):491-5. PubMed ID: 11593323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.
    Koh LP; Koh MB; Ng HY; Hwang WY; Goh YT; Linn YC; Ng HJ; Chuah CT; Tan KW; Loh YS; Tan DC; Tan PH; Tan PH
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):887-90. PubMed ID: 16864060
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
    Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma.
    Bachanova V; Brunstein CG; Burns LJ; Miller JS; Luo X; Defor T; Young JA; Weisdorf DJ; Tomblyn M
    Bone Marrow Transplant; 2009 Feb; 43(3):237-44. PubMed ID: 18806838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning.
    Kalpoe JS; van der Heiden PL; Vaessen N; Claas EC; Barge RM; Kroes AC
    Bone Marrow Transplant; 2007 Jul; 40(2):137-43. PubMed ID: 17530007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation.
    Meers S; Lagrou K; Theunissen K; Dierickx D; Delforge M; Devos T; Janssens A; Meersseman W; Verhoef G; Van Eldere J; Maertens J
    Clin Infect Dis; 2010 Apr; 50(8):1127-34. PubMed ID: 20218875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.